Assessing the Acceptability, Feasibility, Effectiveness and Cost-effectiveness of LADB

Not yet recruitingOBSERVATIONAL
Enrollment

760

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions
Opioid Dependence
Interventions
DRUG

long-acting depot buprenorphine (LADB)

The intervention will measure patient-centered outcomes in people initiating LADB among a cohort of opioid-dependent PWID across sites in the seven project LMIC. Study participants will be enrolled from selected clinics that deliver routine opioid agonist maintenance treatment to PWID. The intervention will 1) Compare characteristics at baseline of those service clients who do and do not initiate LADB in relation to demographic characteristics, history of drug use, and outcomes; 2) Measure side effects and adverse events among those initiating LADB; and 3) Where appropriate, assess changes in outcomes between time of LADB initiation and 48 week follow-up, including HCV and HIV testing and treatment, quality of life, employment opportunities, and service preferences.

All Listed Sponsors
collaborator

UNITAID

OTHER

collaborator

World Health Organization

OTHER

collaborator

Médecins du Monde

OTHER

collaborator

Frontline AIDS

OTHER

collaborator

London School of Hygiene and Tropical Medicine

OTHER

collaborator

International Network of People who Use Drugs

UNKNOWN

collaborator

Monash University

OTHER

collaborator

Population Services International

OTHER

collaborator

Burnet Institute

OTHER

collaborator

University of Bristol

OTHER

collaborator

Alliance for the Public's Health

OTHER

collaborator

Coact Technical Support Limited

UNKNOWN

lead

PATH

OTHER